Shares of Pulmonx Co. (NASDAQ:LUNG – Get Free Report) have earned a consensus rating of “Moderate Buy” from the six ...

Pulmonx Corporation’s LUNG share price has surged by 32.23%, which has investors questioning if this is right time to sell.

Over my first year at Pulmonx, I've been amazed at the impact our technology has on patients' lives and the growing physician and hospital interest in building world class valve and lung health ...

Pulmonx shares were up 23% to $8.20 after the company reported a fourth-quarter loss that was narrower than analysts' expectations.

Pulmonx’s Zephyr ® Endobronchial Valve, Chartis ® Pulmonary Assessment System, LungTraX ™ Platform, and StratX ® Lung Analysis Report are designed to assess and treat patients with severe ...

Pulmonx reported 2024 revenue of $83.8 million ... driven by increased adoption of their Zephyr Valve procedures. The company achieved a gross margin of 74% for both the fourth quarter and ...

The growth in revenue reflects continued commercial momentum and adoption of Zephyr Valve procedures. Gross profit for the full year of 2024 was ... or $1.60 per share, for the same period in 2023.

19, 2025 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq ... reflects continued commercial momentum and adoption of Zephyr Valve procedures. Gross profit for the full year of 2024 was $62.0 ...

Pulmonx achieved Q4 2024 worldwide revenue of $23.8 million, a 23% increase year-over-year, driven by U.S. sales of $15.9 million and international sales of $7.9 million, which grew 16% and 42% ...